UCB0599 PRD4385815

DRUG2 trials

Sponsors

UCB Biopharma, UCB Biopharma, UCB Biopharma

Conditions

Healthy ParticipantsParkinson’s disease

Phase 1

AN OPEN-LABEL, RANDOMIZED STUDY TO EVALUATE THE RELATIVE BIOAVAILABILITY OF A NEW TABLET FORMULATION OF MINZASOLMIN AND THE POTENTIAL EFFECT OF FOOD ON THE PHARMACOKINETICS OF MINZASOLMIN IN HEALTHY PARTICIPANTS

CompletedCTIS2024-511301-31-00

UCB BiopharmaHealthy Participants

Start: 2024-09-06End: 2024-11-17Target: 18Updated: 2024-11-06

Phase 2

A DOSE-BLINDED EXTENSION STUDY TO EVALUATE THE LONG-TERM EFFICACY, SAFETY, AND TOLERABILITY OF UCB0599 IN STUDY PARTICIPANTS WITH PARKINSON’S DISEASE

CompletedCTIS2022-500424-30-00

UCB Biopharma, UCB BiopharmaParkinson’s disease

Start: 2022-12-28End: 2025-03-19Target: 283Updated: 2025-03-03